Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Enzymatic Resolution. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN101974604A reveals a green enzymatic route for paroxetine intermediates using ionic liquids, offering high purity and reduced environmental impact for API manufacturing.
Patent CN110835639A reveals a dual-enzyme DKR process for high-purity (S)-tetrahydroisoquinoline derivatives, offering superior ee values and scalable manufacturing for pharmaceutical intermediates.
Patent CN110317849B reveals a high-yield enzymatic method for producing chiral tetrahydroisoquinoline intermediates, offering significant cost and purity advantages for pharmaceutical manufacturing.
Patent CN1425019A discloses a novel enzymatic route for vitamin D precursors, offering cost reduction in pharmaceutical intermediates manufacturing through scalable crystallization.
Novel synthesis of Aliskiren intermediate via etherification and enzymatic resolution. Reduces steps and cost for API manufacturing significantly.
Novel enzymatic resolution and atmospheric coupling process for high-purity pharmaceutical intermediates ensuring cost reduction and supply reliability.
Novel patent CN109824547A enables safer synthesis of double protected amino acids. Achieve high purity and reduced costs for pharmaceutical intermediate manufacturing supply chains.
Patent CN101448838B details a novel catalytic route for HIV protease inhibitor intermediates, offering significant cost reduction and improved supply chain reliability for antiviral manufacturing.
Novel nickel-catalyzed hydrogenation and lipase resolution method for high-purity 1-acenaphthenol. Enhances safety and yield for global pharmaceutical supply chains effectively.
Novel enzymatic and cobalt-catalyzed route for antiviral intermediate. Reduces toxicity, improves safety, ensures reliable supply chain for pharmaceutical manufacturing.
Advanced enzymatic and chemical separation process for high-purity escitalopram intermediates. Reduces manufacturing costs and improves supply chain reliability for global API producers.
Patent CN101547893B reveals a novel salt recovery method for biphenylalanine, enabling cost reduction in pharmaceutical intermediate manufacturing through direct extraction and recycling.
Patent CN109929822A reveals enhanced lipase mutants for resolving chiral esters. This breakthrough offers significant cost reduction and supply chain reliability for agrochemical intermediate manufacturing.
Novel enzymatic route for high-purity peptide intermediates. Reduces cost and improves scalability for pharmaceutical manufacturing processes globally.
Patent CN109182298B details engineered lipase mutants for high-efficiency resolution of moxifloxacin intermediates, offering significant cost reduction and supply chain reliability.
Patent CN1100144A details enzymatic resolution for high-purity taxane intermediates, offering cost-effective and scalable pharmaceutical manufacturing solutions.
Discover the environmentally friendly synthesis of chiral 2,3-alkenols using lipase catalysis. A breakthrough in pharmaceutical intermediate manufacturing offering high purity and cost efficiency.
Patent CN1240646C details a novel enzymatic process for high-purity (-)-menthol. Discover cost-effective synthetic routes and supply chain advantages for global procurement.
Patent CN1761742A reveals recombinant lactonase technology for efficient D-pantolactone synthesis, offering cost reduction and supply stability for vitamin B5 manufacturers.
Novel enzymatic route for S-indoline-2-carboxylic acid ensures >99% ee purity and simplified processing for reliable pharmaceutical intermediate supply chains.